Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,586 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all

Conditions: Urothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms
Interventions: Cabozantinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urologic Diseases, Urodynamics
Interventions: Glean Urodynamics System; Device
Lead sponsor: Bright Uro; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Murrieta, California • San Diego, California • Cleveland, Ohio

Conditions: Superficial Bladder Cancer
Interventions: ADSTILADRIN; Biological
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 34
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Cancer
Interventions: Oral lapatinib tablets or placebo tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more

Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions: Pazopanib (GW786034), Paclitaxel; Drug
Lead sponsor: Sandy Srinivas; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Stanford, California • Detroit, Michigan

Conditions: Suspicion of Bladder Cancer, NMIBC Surveillance
Interventions: Bladder EpiCheck; Diagnostic Test
Lead sponsor: Nucleix Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: San Diego, California • Towson, Maryland

Conditions: Bladder Cancer
Interventions: Blood draw; Genetic
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions: eCoin Tibial Nerve Stimulation; Device
Lead sponsor: Valencia Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 22
States / cities: Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 18 more

Conditions: Interstitial Cystitis
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Neurogenic Bladder
Interventions: Autologous neobladder construct; Device
Lead sponsor: Tengion; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tumor
Interventions: ipilimumab, nivolumab, ENHANZE (rHuPH20); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Hartford, Connecticut • Fort Wayne, Indiana

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Neoadjuvant Cisplatin and Gemcitabine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, New York • Portland, Oregon

Conditions: Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer, GastroEsophageal Cancer, Renal Cell Carcinoma, MSI-H
Interventions: EDP1503, Pembrolizumab; Biological
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more

Conditions: Bladder Carcinoma
Interventions: Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Other · Dietary Supplement
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 46
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 35 more

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND); Biological · Other · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more

Conditions: Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD; Biological · Drug
Lead sponsor: Toray Industries, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 13
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more

Conditions: Neoplasms, Cancer, Caregiver
Interventions: Not listed
Lead sponsor: Cancer Support Community, Research and Training Institute, Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Bladder Cancer
Interventions: Gemcitabine, E7389, Cisplatin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Myers, Florida + 11 more

Conditions: Bladder Cancer
Interventions: Docetaxel, ZD1839, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: chemotherapy, tipifarnib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 2
States / cities: San Francisco, California • Tampa, Florida

Conditions: Overactive Bladder
Interventions: Botulinum toxin and cineMRI-UDS; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Lapatinib and Paclitaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Urinary Incontinence
Interventions: tolterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lower Urinary Tract Symptoms
Interventions: None-observational, Magnetic Resonance Imaging (MRI), Multimodal Automated Sensory Testing System, Auditory Sensitivity Test; Other · Procedure
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years and older
Enrollment: 1,879 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 3 more

Search by objective public record fields.

Cabozantinib for Advanced Urothelial Cancer

Trial for Reliability of Urodynamics SysTem

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Bladder EpiCheck Product Development Study

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

Urinary Biomarkers Characteristic to Interstitial Cystitis

Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

R115777 in Treating Patients With Advanced Bladder Cancer

The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study